Alpha DNA Investment Management LLC Purchases New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Alpha DNA Investment Management LLC acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,732 shares of the company’s stock, valued at approximately $430,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. O Shaughnessy Asset Management LLC lifted its position in shares of Neurocrine Biosciences by 16.8% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 3,695 shares of the company’s stock worth $510,000 after purchasing an additional 531 shares during the period. UniSuper Management Pty Ltd grew its holdings in shares of Neurocrine Biosciences by 100.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 1,400 shares of the company’s stock worth $193,000 after acquiring an additional 700 shares during the period. Lazard Asset Management LLC raised its position in shares of Neurocrine Biosciences by 19.1% in the 1st quarter. Lazard Asset Management LLC now owns 55,329 shares of the company’s stock worth $7,630,000 after acquiring an additional 8,884 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in Neurocrine Biosciences by 6.6% in the first quarter. Public Employees Retirement System of Ohio now owns 47,947 shares of the company’s stock worth $6,613,000 after purchasing an additional 2,987 shares in the last quarter. Finally, Bayesian Capital Management LP lifted its position in Neurocrine Biosciences by 43.9% during the first quarter. Bayesian Capital Management LP now owns 12,453 shares of the company’s stock valued at $1,718,000 after buying an additional 3,800 shares during the period. 92.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Robert W. Baird upped their price target on Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. HC Wainwright reiterated a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Friday, November 1st. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $125.65 on Monday. Neurocrine Biosciences, Inc. has a 12 month low of $110.52 and a 12 month high of $157.98. The company has a market capitalization of $12.72 billion, a price-to-earnings ratio of 33.69 and a beta of 0.35. The firm’s fifty day moving average price is $118.62 and its 200 day moving average price is $131.94.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.